GLPG Stock Overview
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Galapagos NV Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €29.58 |
52 Week High | €41.92 |
52 Week Low | €29.45 |
Beta | 0.027 |
1 Month Change | -13.13% |
3 Month Change | -20.03% |
1 Year Change | -14.29% |
3 Year Change | -56.10% |
5 Year Change | -73.01% |
Change since IPO | 84.88% |
Recent News & Updates
Recent updates
Galapagos NV's (AMS:GLPG) Shares Lagging The Industry But So Is The Business
Jan 03Lacklustre Performance Is Driving Galapagos NV's (AMS:GLPG) Low P/S
Jul 18€41.78: That's What Analysts Think Galapagos NV (AMS:GLPG) Is Worth After Its Latest Results
May 06Here's Why We're Not Too Worried About Galapagos' (AMS:GLPG) Cash Burn Situation
Mar 29Shareholder Returns
GLPG | NL Biotechs | NL Market | |
---|---|---|---|
7D | -3.8% | -0.6% | 0.1% |
1Y | -14.3% | -3.2% | 17.7% |
Return vs Industry: GLPG underperformed the Dutch Biotechs industry which returned -2.7% over the past year.
Return vs Market: GLPG underperformed the Dutch Market which returned 19.3% over the past year.
Price Volatility
GLPG volatility | |
---|---|
GLPG Average Weekly Movement | 3.7% |
Biotechs Industry Average Movement | 7.5% |
Market Average Movement | 3.7% |
10% most volatile stocks in NL Market | 8.0% |
10% least volatile stocks in NL Market | 2.3% |
Stable Share Price: GLPG's share price has been volatile over the past 3 months.
Volatility Over Time: GLPG's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 1,233 | Paul Stoffels | https://www.glpg.com |
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis.
Galapagos NV Fundamentals Summary
GLPG fundamental statistics | |
---|---|
Market cap | €1.95b |
Earnings (TTM) | -€3.99m |
Revenue (TTM) | €239.72m |
8.1x
P/S Ratio-488.8x
P/E RatioIs GLPG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GLPG income statement (TTM) | |
---|---|
Revenue | €239.72m |
Cost of Revenue | €241.29m |
Gross Profit | -€1.57m |
Other Expenses | €2.42m |
Earnings | -€3.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | -0.061 |
Gross Margin | -0.65% |
Net Profit Margin | -1.66% |
Debt/Equity Ratio | 0% |
How did GLPG perform over the long term?
See historical performance and comparison